Clinical Study
The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study
Table 2
Outcomes at the 3-month and 6-month follow-ups.
| | Vitamin D2 | Placebo | p-value |
| At baseline | | | | PASI, mean±SD | 4.68±3.12 | 4.21±2.53 | 0.58 | At 3-month follow-up | | | | PASI, mean±SD | 3.11±2.43 | 4.73±3.94 | 0.13 | PASI change, mean±SD | 1.43±1.94 | -0.33±2.95 | 0.03 | %PASI change, mean±SD | 34.21%±35.24 | -1.85%±66.73 | 0.039 | At 6-month follow-up | | | | PASI, mean±SD | 2.39±1.97 | 3.35±2.49 | 0.20 | PASI change, mean±SD | 2.15±2.59 | 0.71±1.83 | 0.055 | %PASI change, mean±SD | 42.79%±36.18 | 21.57%±53.22 | 0.16 |
|
|
PASI, Psoriasis Area and Severity Index; SD, standard deviation.
|